- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03710174
Evaluation of the Effectiveness of Infrared LED Photobiomodulation in Children With Sleep Bruxism
October 15, 2018 updated by: Fernanda Yukie Kobayashi, University of Nove de Julho
Evaluation of the Effectiveness of Infrared LED Photobiomodulation in Children With Sleep Bruxism: Study Protocol for Randomized Clinical Trial.
Sleep bruxism is a masticatory muscle activity characterized as rhythmic (phasic) or non-rhythmic (tonic).
The literature reports the prevalence rates, diverse etiologies and different types of treatment.
In children and adolescents, etiological factors, such as breathing pattern and sleep quality, have recently been addressed in studies investigating sleep bruxism.
While studies have also reported psychological factors as a causal factor, this aspect requires further research.
There are also divergences in opinion regarding the form of treatment.
New therapies for adults, such as botulinum toxin, have been investigated, but such techniques are not applicable for individuals in the growth and development phase.
Thus, photobiomodulation therapy has piqued the interest of researchers, as this noninvasive method has demonstrated positive results in problems related to muscle tissues.
This document describes the protocol for a proposed study to evaluate morphological and psychosocial aspects in children and adolescents with awake bruxism and their responses to photobiomodulation therapy with infrared LED.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
SP
-
São Paulo, SP, Brazil, 01504-001
- Recruiting
- UniNove
-
Contact:
- Fernanda Kobayashi
- Phone Number: +55 11 3385 9010
- Email: fernandaykobayashi@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
7 years to 10 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- mixed dentition phase (permanent incisors and molars erupted)
- established permanent dentition.
Exclusion Criteria:
- dental caries
- using medications, such as anti-inflammatory agents, muscle relaxants, corticoids, anticonvulsants and antidepressants
- those with chronic diseases that affect muscles or motor coordination
- those who do not cooperate during the evaluation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control group
Without bruxism and no intervention.
They will be submitted to electromyographic assessment and evaluation of salivary cortisol and dopamine.
|
|
Experimental: LED group
The volunteers in Group 2 will be submitted to the initial evaluation of the morphological and psychosocial variables.
During the same appointment, red LED (3 X 6 cm) will be administered using a board with 6 LEDs with a wavelength of 650 nm ± 20 nm, seven-minute operation time, optical spot of 5 ± 2 mm and optical output of 2~5 mW, with a dose of 2.675 J/cm2.
Further analyses will be performed immediately after the photobiomodulation session and one week later.
They will be submitted before and after LED to electromyographic assessment and evaluation of salivary cortisol and dopamine.
|
Infrared LED (3 X 6 cm) will be administered using a board with 6 LEDs with a wavelength of wavelength: 850 nm ± 20 nm, seven-minute operation time, optical spot of 5 ± 2 mm and optical output of 2~5 mW, with a dose of 2.675 J/cm2.
Further analyses will be performed immediately after the photobiomodulation session and one week later.
|
Experimental: Occlusal splint group
They will be treated using the standard protocol of a rigid occlusal splint.
After the initial evaluation, molds will be made for the fabrication of the splints, which will be delivered one week later.
Written and verbal instructions for use will be given.
After one month of daily use, the volunteers will return for the final morphological and psychosocial evaluations.
|
After the initial evaluation, molds will be made for the fabrication of the splints, which will be delivered one week later.
Written and verbal instructions for use will be given.
After one month of daily use, the volunteers will return for the final morphological and psychosocial evaluations.
|
Placebo Comparator: Placebo group
Subjects with bruxism.
The same procedures as LED group, but the device will be turn off.
|
The same procedure as LED group with the device turned off.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in muscle activity evaluated by electromyography
Time Frame: Before and immediately after treatment
|
Electromyography will be performed to complement the evaluation of the morphological aspects of the groups.
The masseter and temporal muscles will be evaluated using a portable electromyograph (BTS TMJOINT) with wireless electrodes.
The participant will be seated with Camper's plane parallel to the floor.
Three readings will be made on both sides with the muscles at rest, during habitual maximum intercuspation (isometric contraction) and during simulated chewing with Parafilm (isotonic contraction).
The signal will be captured for 10 seconds under each condition.
The first chewing cycle will be discarded and the subsequent five cycles will be collected.
|
Before and immediately after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in salivary cortisol and dopamine
Time Frame: Before and immediately after treatment
|
The participants and caregivers will receive verbal and written instructions to avoid any physical activity, the ingestion of substances with alcohol or caffeine, soft drinks, tea, corticoids and chewing gum in the 24h prior to the collection of the saliva.
Saliva samples will be collected using swabs, which will refrigerated immediately after collection.
The swab will be placed under the tongue.
Samples with visible signs of blood will be discarded due to possible contamination.
The swabs will be centrifuged at 3500 rpm for 5 minutes.
The supernatant will be collected and stored at -40o C. Cortisol will be determined using an enzyme-linked immunosorbent assay.
Dopamine will also be determined using an ELIZA kit.
The samples will be thawed and centrifuged again.
The procedure will follow the basic ELISA principle of competition between an untagged antigen and an enzyme-tagged antigen for a particular number of binding sites on the antibody.
|
Before and immediately after treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2017
Primary Completion (Actual)
August 1, 2018
Study Completion (Anticipated)
April 10, 2019
Study Registration Dates
First Submitted
October 15, 2018
First Submitted That Met QC Criteria
October 15, 2018
First Posted (Actual)
October 18, 2018
Study Record Updates
Last Update Posted (Actual)
October 18, 2018
Last Update Submitted That Met QC Criteria
October 15, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ferbruxismo
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bruxism, Sleep
-
CES UniversityNot yet recruitingSleep Bruxism, Childhood
-
Aydin Adnan Menderes UniversityCompleted
-
Istanbul UniversityCompletedSleep | Splints | Sleep Bruxism, AdultTurkey
-
University of California, San FranciscoWithdrawn
-
Dominik EttlinMerz PharmaceuticalsNot yet recruiting
-
Federal University of PelotasUnknown
-
University of Nove de JulhoNot yet recruitingSleep Bruxism | Sleep Bruxism, Childhood
-
Hasan Kalyoncu UniversityCompletedSleep Bruxism, ChildhoodTurkey
-
Hospices Civils de LyonCompletedBruxism, Sleep-RelatedFrance
-
Federal University of PelotasCompletedSleep Bruxism, AdultBrazil
Clinical Trials on Infrared LED photobiomodulation
-
Quietmind FoundationMaculume Ltd.Completed
-
Gaitway NeurophysioRecruitingDisease | Parkinson'sCanada
-
University of Nove de JulhoUnknownTemporomandibular DisorderBrazil
-
University of Nove de JulhoUnknown
-
Arash Asher, MDThorNot yet recruitingCancer-related Cognitive ImpairmentUnited States
-
University of Nove de JulhoCompleted
-
Centre Oscar LambretFondation Apicil; Santelys AssociationCompletedOral Cancer | Oropharyngeal CancerFrance
-
MindLight, LLCHarvard Medical School (HMS and HSDM); National Institute on Drug Abuse (NIDA) and other collaboratorsCompletedOpioid Dependence | Opioid Abuse | Opioid-use DisorderUnited States
-
University of Nove de JulhoNot yet recruiting
-
Federal University of Health Science of Porto AlegreCompleted